

Supplementary Table 3. Treatment efficacy inputs

Drug	Barrionuevo et al. [33] ^{a)}				Freemantle et al. [34] ^{a)}			
	Hip fracture	Vertebral fracture	Wrist fracture	Other fracture	Hip fracture	Vertebral fracture	Wrist fracture	Other fracture
Alendronate	0.61	0.57	0.84	0.84	0.63	0.57	0.82	0.83
Ibandronate (IV)	0.62	0.67	1.06	1.06	1	0.50	1	1.11
Ibandronate (oral)	0.62	0.67	1.06	1.06	1	0.50	1	1.11
Risedronate	0.73	0.61	0.78	0.78	0.75	0.62	0.67	0.80
Raloxifene	0.91	0.59	0.94	0.94	1	0.63	1	0.87
Zoledronate	0.60	0.38	0.79	0.79	0.58	0.30	0.76	0.75
Denosumab	0.56	0.32	0.80	0.80	0.60	0.32	0.84	0.81

^{a)}Network meta-analysis studies which provides comparative effective estimates for various antiosteoporosis drugs in reducing the risk of osteoporotic fractures.